TABLE 6

Dose regimens based on renal function to provide similar cefiderocol exposure among renal function groups and >90% of PTA for 75% Tf>MIC against an MIC of ≤4 μg/ml

Renal functionDose regimen
Augmented (CG-CLCR, ≥120 ml/min)2 g q6h, 3-h infusion
Normal (MDRD-eGFR, ≥90 ml/min/1.73 m2)2 g q8h, 3-h infusion
Mild impairment (MDRD-eGFR, 60 to <90 ml/min/1.73 m2)2 g q8h, 3-h infusion
Moderate impairment (MDRD-eGFR, 30 to <60 ml/min/1.73 m2)1.5 g q8h, 3-h infusion
Severe impairment (MDRD-eGFR, 15 to <30 ml/min/1.73 m2)1 g q8h, 3-h infusion
ESRD (MDRD-eGFR, <15 ml/min/1.73 m2)0.75 g q12h, 3-h infusion
Requiring intermittent HD0.75 g q12h, 3-h infusiona
  • a A supplemental (third) dose of 0.75 g with a 3-h infusion is administered after the completion of intermittent HD on dialysis days.